Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® Quadrivalent): A review of its use in the prevention of disease caused by influenza A and B

Drugs

Volumn 73, Issue 14, 2013, Pages 1587-1594

  McKeage, Kate ^a  

^a Adis   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEASONS; VACCINATION; VACCINES, INACTIVATED;

EID: 84893207618     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0114-3     Document Type: Review

References (30)

1. US Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 [published errata appear in MMWR Recomm Rep. 2010; 59(31):993 and 2010; 59(35):1147. MMWR Recomm Rep. 2010; 59(rr-8):1-62
2. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190(8): 1369-73
3. World Health Organization (WHO). WHO position paper: vaccines against influenza [online]. 2012. http://www. who. int/ immunization/position-papers/PP- influenza-november2012- summary. pdf. Accessed 3 Jul 2013
4. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292 (11):1333-40
5. US Centers for Disease Control and Prevention (CDC). Estimates of death associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010; 59(33): 1057-62
6. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96
7. US Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP): United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2012; 61(32):613-18
8. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81-8
9. Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28(9): 2149-56
10. GlaxoSmithKline. Fluarix- Quadrivalent (influenza virus vaccine): full prescribing information. 2013. http://us. gsk. com/ products/assets/us-fluarix- quadrivalent. pdf. Accessed 24 Jul 2013
11. Curran MP, Leroux-Roels I. Inactivated split-virion seasonal influenza vaccine (Fluarix-): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs. 2010;70 (12):1519-43
12. Kieninger D, Lin W-Y, Yu CJ, et al. Immunogenicity and safety profile of a candidate inactivated quadrivalent influenza vaccine in adults and the elderly: a randomized controlled study [abstract]. In: 4th International Conference and Exhibition on Influenza Vaccines for the World; 9-12 Oct 2012; Valencia
13. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207(12):1878-87
14. Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013; 13:224
15. U. S. Food and Drug Administration Department of Health and Human Services. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. 2007. http://www. fda. gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/ Vaccines/ucm091990. pdf. Accessed 16 Jul 2013
16. European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96) [online]. 1997. http://www. ema. europa. eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003945. pdf. Accessed 23 Jun 2013
17. Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis. 2009;200(12):1861-9
18. Hehme NW, Kunzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, FluarixTM. Clin Drug Investig. 2002;22(11):751-69
19. Meier G, Van Bellinghen LA, Van Vlaenderen I. Potential benefits analysis of quadrivalent influenza vaccine (QIV) on influenza disease burden in the United Kingdom, year by year analysis (2000-2010) [abstract]. In: International Society for Pharmacoeconomics and Outcomes Research 18th Annual Meeting 18-22 May 2013; New Orleans, LA
20. Meier G, Clements KM, McGarry L, et al. Universal mass vaccination with quadrivalent influenza vaccine (QIV) in the United States [abstract]. In: International Society for Pharmacoeconomics and Outcomes Research 18th Annual Meeting 18-22 May 2013; New Orleans, LA
21. Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153
22. Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs. 2012;72(17): 2177-85
23. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010;28(Suppl 4):D45-53
24. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine. 2005;23(Suppl 1):S10-25
25. Australian and New Zealand Society for Geriatric Medicine. Immunisation of older people: revision number 2. 2011. http:// www. anzsgm. org/documents/PS7Immunisation300811-000. pdf. Accessed Jul 26 2013
26. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-86
27. Hu JJ, Kao CL, Lee PI, et al. Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect. 2004;37(2):95-8
28. Hite LK, Glezen WP, Demmler GJ, et al. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis. 2007;11(1):40-7
29. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003;36(3):299-305
30. Reed C, Meltzer MI, Finelli L, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993-8.